Trial Search Results
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of idelalisib in patients with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is refractory both to rituximab and to alkylating-agent-containing chemotherapy. The primary objective will be to assess the overall response rate.
Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg taken twice per day. Treatment with idelalisib can continue in compliant patients as long as the study is still ongoing and the patients appear to be benefiting from treatment with acceptable safety.
Stanford is currently not accepting patients for this trial.
- Drug: Idelalisib
Key Inclusion Criteria:
- Age ≥ 18 years
- Karnofsky performance score of ≥ 60 (Eastern Cooperative Oncology Group [ECOG]
performance score of 0, 1, or 2)
- Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited
to the following:
- Follicular lymphoma (FL)
- Small lymphocytic lymphoma (SLL) with absolute lymphocyte count
- Lymphoplasmacytic lymphoma (LPL), with or without associated Waldenstroms
- Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal)
- Prior treatment with ≥ 2 prior chemotherapy-based or immunotherapy-based regimens for
- Presence of radiographically measurable lymphadenopathy or extranodal lymphoid
- Prior treatment with rituximab and with an alkylating agent (eg, bendamustine,
cyclophosphamide, ifosfamide, chlorambucil, melphalan, busulfan, nitrosoureas) for
- Lymphoma that is refractory to rituximab and to an alkylating agent
- Discontinuation of all other therapies for treatment of iNHL ≥ 3 weeks before Visit 2
- For men and women of childbearing potential, willingness to abstain from sexual
intercourse or employ an effective method of contraception during the study drug
administration and follow-up periods
- Willingness and ability to provide written informed consent and to comply with the
Key Exclusion Criteria:
- Central nervous system or leptomeningeal lymphoma
- Known histological transformation from iNHL to diffuse large B-cell lymphoma.
- History of a non-lymphoma malignancy except for the following: adequately treated
local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ,
superficial bladder cancer, localized prostate cancer, other adequately treated Stage
1 or 2 cancer currently in complete remission, or any other cancer that has been in
complete remission for ≥ 5 years
- Evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral
upper respiratory tract infections) at the time of initiation of study treatment
- Pregnancy or breastfeeding
- Ongoing alcohol or drug addiction
- Known history of drug-induced liver injury, chronic active hepatitis B infection,
chronic active hepatitis C infection, alcoholic liver disease, non-alcoholic
steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by
stones, cirrhosis of the liver, or portal hypertension
- History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
- Ongoing immunosuppressive therapy, including systemic corticosteroids. Patients may be
using topical or inhaled corticosteroids.
- Prior therapy with idelalisib
- Exposure to another investigational drug within 3 weeks prior to start of study
- Concurrent participation in another therapeutic treatment trial.
- Prior or ongoing clinically significant illness, medical condition, surgical history,
physical finding, ECG finding, or laboratory abnormality that, in the investigator's
opinion, could affect the safety of the patient, alter the absorption, distribution,
metabolism or excretion of the study drug, or impair the assessment of study results
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study